Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia

Blood

Volumn 112, Issue 5, 2008, Pages 1876-1885

  Quintarelli, Concetta ^a,c   Dotti, Gianpietro ^a   De Angelis, Biagio ^a,b,c   Hoyos, Valentina ^a   Mims, Martha ^a   Luciano, Luigia ^b   Heslop, Helen E ^a   Rooney, Cliona M ^a   Pane, Fabrizio ^b,c   Savoldo, Barbara ^a,d  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^d CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; HLA A ANTIGEN; OX40 LIGAND; PRAME ANTIGEN; UNCLASSIFIED DRUG; HLA A*02 ANTIGEN; HLA-A*02 ANTIGEN; MESSENGER RNA; PRAME PROTEIN, HUMAN; RNA; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CELL COMPARTMENTALIZATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; BIOSYNTHESIS; CELL LINE; CELL STRAIN K 562; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY; TUMOR CELL LINE;

ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CELL LINE; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; RNA, MESSENGER; RNA, NEOPLASM; T-LYMPHOCYTES, CYTOTOXIC;

EID: 52649135956     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-150045     Document Type: Article

References (48)

1. Hehlmann R, Berger U, Pfimmann M, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood. 2007;109:4686-4692.
2. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640-2653.
3. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006:355:2408-2417.
4. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820.
5. Goldman JM, Melo JV. Chronic myeloid leukemiaadvances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-1464.
6. Dazzi F, Szydlo RM, Goldman JM. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol. 1999:27:1477-1486.
7. Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control. 2002;9:123-137.
8. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86: 4337-4343.
9. Kolb HJ, Schmid C, BarrettAJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103:767-776.
10. Molldrem JJ, Glave E, Jiang YZ, et al. CytotoxicT lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997; 90:2529-2534.
11. Molldrem JJ, Lee PP. Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 1999;59:2675-2681.
12. Rezvani K, Yong AS, Mielke S, et al. Leukemiaassociated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008:111:236-242.
13. Yotnda P, Firat H, Garcia-Pons F, et al. Cytotoxic Tcell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest. 1998;101:2290-2296.
14. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005;365:657-662.
15. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002;188:22-32.
16. Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med. 2001;193:73-88.
17. Paydas S, Tanriverdi K, Yavuz S, Seydaoglu G. PRAME mRNA levels in cases with chronic leukemia: clinical importance and review of the literature. Leuk Res. 2007;31:365-369.
18. Epping MT, Wang L, Edel MJ, et al. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005;122: 835-847.
19. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92: 1549-1555.
20. Molldrem JJ, Lee PP. Kant S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 2003;111:639-647.
21. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood. 2004;103:2046-2054.
22. Biagi E, Dotti G, Yvon E, et al. Molecular transfer of GD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Blood. 2005;105: 2436-2442.
23. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
24. Kawashima I, Hudson SJ, Tsai V, et al. The multiepitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998;59:1-14.
25. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999;10: 673-679.
26. Minev B, Hipp J, Firat H, et al. Cytotoxic Tcell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A. 2000; 97:47g6-4801.
27. Wolfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol. 1994;24:759-764.
28. Anichini A, Molla A, Mortarini R, et al. An expanded peripheral T cell population to a cytotoxic Tlymphocyte (GTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med. 1999;190: 651-667.
29. Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002;100:4059-4066.
30. Savoldo B, Rooney CM, Quiros-Tejeira RE, et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant. 2005;5:566-572.
31. Alimena G, Breccia M, Luciano L, et al. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate. Leuk Res. 2008; 32:255-261.
32. Palandri F, lacobucci I, Martinelli G, et al. Longterm outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. J Clin Oncol. 2008;26:106-111.
33. Sili U, Huls MH, Davis AR, et al. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother. 2003;26:241-256.
34. Gahn B, Siller-Lopez F, PiroozAD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer. 2001;93:706-713.
35. Quintarelli C. Vera JF. Savoldo B, et al. Coexpression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007;110:2793-2802.
36. Banavali S, Silvestri F, Hulette B, et al. Expression of hematopoietic progenitor cell associated antigen CD34 in chronic myeloid leukemia. Leuk Res. 1991;15:603-608.
37. Lanza F, Moretti S, Castagnari B, et al. CD34+ leukemic cells assessed by different CD34 monoclonal antibodies. Leuk Lymphoma. 1995;18 Suppl 1:25-30.
38. Biagi E, Rousseau R, Yvon E, et al. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2005;11: 6916-6923.
39. Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology (Am Soc Hematol Educ Program). 2003;331-349.
40. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 2001;24: 363-373.
41. Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006;108:2942-2949.
42. Bollard CM, Aguilar L, Straathof KG, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004:200: 1623-1633.
43. Straathof KC, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specificT lymphocytes. Blood. 2005; 105:1898-1904.
44. Savoldo B, Cubbage ML, Durett AG, et al. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002; 168:909-918.
45. Griffioen M, Kessler JH, Borghi M, et al. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res. 2006;12:3130-3136.
46. Teague RM, Sather BD, Sacks JA, et al. lnterleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med. 2006;12:335-341.
47. Gottschalk S, Ng CY, Perez M, et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific GTLs. Blood. 2001;97: 835-843.
48. Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res. 2007:31: 1521-1528.